Diphtheria fusion protein therapy of chemoresistant malignancies

Current Cancer Drug Targets

Volumn 2, Issue 1, 2002, Pages 19-36

  Frankel, Arthur E ^a   Rossi, Patrick ^b   Kuzel, Timothy M ^c   Foss, Francine ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b INTELLIgene Expressions Inc   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; TF CRM 107; UNCLASSIFIED DRUG;

ASTHENIA; BRAIN INJURY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CATALYSIS; CELL DAMAGE; CELL DIVISION; CELL SELECTION; CLINICAL TRIAL; COVALENT BOND; DIPHTHERIA; DRUG HYPERSENSITIVITY; EDEMA; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; LIGAND BINDING; LIVER FAILURE; LYSIS; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; PROTEIN DOMAIN; PROTEIN SYNTHESIS; PROTEINURIA; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; UREMIA; VOMITING;

ANIMALS; CLINICAL TRIALS; DIPHTHERIA TOXIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 0036286543     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023333944     Document Type: Review

References (152)

1. Enteric Bacterial Toxins: Mechanisms of Action and Linkage to Intestinal Secretion
2. Staphylococcal Alpha-Toxin, Streptolysin-O and Escherichia coli Hemolysin: Prototypes of Pore-Forming Bacterial Cytolysins
3. Biology and molecular epidemiology of diphtheria toxin and the tox gene
4. The relationship existing between chemical constitution, distribution, and pharmacologic action
5. Selective destruction by diphtheria toxin conjugated to antibody directed against antigens on the cells
6. Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40
7. Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta
8. The complete nucleotide sequence of the gene coding for diphtheria toxin in the Corynephage Omega (tox+) Genome
9. The crystal structure of Diphtheria toxin
10. Crystal structure of nucleotide-free diphtheria toxin
11. Molecular characterization of key diphtheria toxin: Receptor interactions
12. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor
13. Cell surface monkey CD9 antigen is a coreceptor that increases diphtheria toxin sensitivity and diphtheria toxin receptor affinity
14. Heparin-like molecules on the cell surface potentiate binding of diphtheria toxin to the diphtheria toxin receptor/membrane-anchored heparin-binding epidermal growth factor-like growth factor
15. GPI-anchored diphtheria toxin receptor allows membrane translocation of the toxin without detectable ion channel activity
16. The effect of receptor rapid-internalization signals on diphtheria toxin endocytosis and cell sensitivity
17. Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin
18. Membrane translocation of diphtheria toxin fragment a exploits early to late endosome trafficking machinery
19. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases
20. Mutational analysis of the helical hairpin region of diphtheria toxin transmembrane domain
21. Penetration of protein toxins into cells
22. Inhibition of membrane translocation of diphtheria toxin a-fragment by internal disulfide bridges
23. Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol
24. Cell-mediated reduction and incomplete membrane translocation of diphtheria toxin mutants with internal disulfides in the a fragment
25. Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin
26. Diphthamide in elongation factor 2: ADP-ribosylation, purification, and properties
27. Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages
28. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide
29. Molecular movement inside the translational engine
30. Three-dimensional cryo-electron microscopy localization of EF2 in the saccharomyces cerevisiae 80S ribosome at 17.5 Å resolution
31. Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis
32. Role of caspases in immunotoxin-induced apoptosis of cancer cells
33. One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell
34. Defective acidification of endosomes in chinese hamster ovary cell mutants cross-resistant to toxins and viruses
35. Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and pseudomonas exotoxin A. Genetic and biochemical analysis
36. The mechanism of ADP-ribosylation of elongation factor 2 catalyzed by fragment A from diphtheria toxin
37. Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates: Potential role of the hydrophobic domain in toxin entry
38. Cloned fragment of DT linked to T-cell specific antibody identifies regions of B chain active in cell entry
39. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein
40. Protein engineering of diphtheria toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells
41. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells
42. Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model
43. Mutation in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity
44. Enhancement of immunotoxinefficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants
45. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins
46. Epidermal growth factor-toxin a chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic
47. Extension of juxtamembrane domain of diphtheria toxin receptor arrests translocation of diphtheria toxin fragment A into cytosol
48. 486IL-2): Fragment B sequences required for the delivery of fragment A to the cytosol of target cells
49. Structure/Function Analysis of the Transmembrane Domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin
50. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials
51. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias
52. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor
53. 390-mIL-3), with bone marrow progenitor cells
54. Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389-mIL3 and DAB389-(G4S)2-mIL3
55. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion
56. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells
57. Interaction of an α-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases
58. In vivo T cell depletion in miniature swine using the swine CD3 immunotoxin, Pcd3-CRM9
59. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth
60. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: Role of plasma kinetics, capillary permeability and binding
61. The role of diphtheria toxin receptor in cytosol translocation
62. An antibody-toxin conjugate directed against a human mammary cancer antigen
63. Antibody-directed cytotoxic agents: Use Of monoclonal antibody to direct the action of toxin a chains to colorectal carcinoma cells
64. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors
65. Phase II trial of convection-enhanced distribution of recombinant immunotoxin in patients with recurrent malignant gliomas
66. 389EGF in patients with solid malignancies that express EGF receptors (EGFr)
67. Diphtheria toxin fusion proteins
68. Resistant acute myeloid leukemia responds to a novel diphtheria toxin/GM-CSF fusion protein: Summary of an ongoing phase I trial
69. Phase I trial of an interleukin-2 fusion toxin (DAB4861L-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy
70. 486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies
71. 486IL-2 in hematologic cancers
72. 486IL-2) in hematologic malignancies expressing the IL-2 receptor
73. Chimeric fusion protein toxin DAB4861L-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study
74. DAB486IL2 fusion toxin in refractory rheumatoid arthritis
75. 486IL-2) in refractory rheumatoid arthritis
76. 486IL-2) in patients with refractory rheumatoid arthritis
77. Phase I trial of a ligand-fusion protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2
78. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
79. Combination of ONTAK and steroids is associated with a significantly improved response rate in refractory CTCL
80. Treatment of relapsed refractory peripheral T-cell lymphoma with Denileukin Diftitox (ONTAK): A case report of one patient
81. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
82. Administration of DAB3891L-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial
83. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-Cell lymphoma
84. Diphtheria toxin-related cytokine fusion proteins: Elongation factor 2 as a target for the treatment of neoplastic disease
85. Therapeutic effects of genetically engineered toxin (DAB4861L-2) in patient with chronic lymphocytic leukaemia
86. Use of the interleukin-2 (IL-2) fusion protein, DAB3891L-2, for the treatment of psoriasis
87. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107
88. Diphtheria toxin fused to human granulocyte-macrophage colony stimulating factor (DTGM) triggers cytokine release from normal but NOT malignant human mononuclear cells in cell culture: An in vitromodel of the systemic inflammatory response syndrome (SIRS)
89. Toxic ligand conjugates as tools in the study of receptor-ligand interactions
90. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma
91. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma
92. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: Insights into toxin-mediated vascular damage
93. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with nonHodgkin's lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials
94. Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplantation recipients
95. Antibody response to DTGM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia
96. Pharmacologic and immunologic studies of a diphtheria fusion protein in patients with relapsed or refractory AML
97. Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface
98. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
99. 389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma
100. 389IL-2 fusion toxin in mycosis fungoides
101. In vitro and in vivo effects of the DAB389EGF fusion toxin on human glioblastoma cells
102. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
103. A diphtheria toxin-interleukin-3 fusion protein is cytotoxic to acute myeloid leukemia (AML) stem cells but spares normal stem cells
104. Potent antitumour activity of a new class of tumour-specific killer cells
105. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene
106. Gene therapy of murine solid tumors with T cells transduced with a retroviral VEGF immunotoxin target gene
107. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
108. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer
109. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells
110. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF
111. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line
112. Anti-graft-versus-Hhst disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 Epsilon moiety of the T-cell receptor
113. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3
114. A new reagent for the induction of T cell depletion, anti-CD3-CRM9
115. 389IL-2 in cultured hematopoietic cells
116. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein
117. A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-depedent tumor cells
118. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia
119. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: A potential vector for delivering heterologous proteins to neurons
120. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor
121. Genetic construction and properties of a diphtheria toxin-related substance P fusion protein: In vitro destruction of cells bearing substance P receptors
122. Actions of intrathecal diphtheria toxin-substance P fusion protein on models of persistent pain
123. Inhibition of AIDS-associated Kaposi's sarcoma cell growth by DAB389-interleukin 6
124. Site-directed and deletion mutational analysis of the receptor binding domain of the interleukin-6 receptor targeted fusion toxin DAB389-IL-6
125. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
126. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitroand angiogenesis in vivo
127. Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immunotoxin
128. 389IL-7: A novel agent for the elimination of IL-7 receptor positive cells
129. Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes
130. IL-4R expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB389-IL-4)
131. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene
132. Interleukin 4 receptor targeted cytotoxicity: Genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein
133. Diphtheria toxin-related α-melanocyte-stimulating hormone fusion toxin
134. Genetic construction, expression and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein
135. Diphtheria toxin-related fusion protein DAB389GRP
136. Synthesis and cytotoxic profile of a diphtheria toxin-neurotrophin-4 chimera
137. A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express Gp120 but selects fusion toxin resistant cells which carry HIV
138. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin β1
139. Chimeric toxins: Toxic, disulfide-linked conjugate of concanavalin a with fragment a from diphtheria toxin
140. Lectin-carbohydrate interactions: Different folds, common recognition principles
141. Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates
142. Receptor-mediated transport of the hybrid protein ricin-diphtheria toxin fragment A with subsequent ADP-ribosylation of intracellular elongation factor II
143. 389sIL-15
144. Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin a chain
145. Reconstitution of hybrid toxin from fragment a of diphtheria toxin and a subunit of wistaria floribunda lectin
146. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate
147. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells
148. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule
149. Preparation of an immunotoxin for acanthamoeba castellanii
150. Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by Simian virus 40